GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

GlaxoSmithKline (GSK) has announced that Arexvy, its respiratory syncytial virus (RSV) vaccine, has received expanded ...

In addition to Bank of America Securities, GlaxoSmithKline also received a Hold from UBS’s Matthew Weston in a report issued on January 21. However, on January 22, J.P. Morgan maintained a Sell rating ...

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

ETHealthworld.com brings latest glaxosmithkline pharmaceuticals news, views and updates from all top sources for the Indian Health industry.

GSK (GSK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...

The acquisition was announced on Tuesday, News.Az reports, citing Reuters. This marks GSK's first major purchase under the ...

GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation (RI&I) as well as oncology, through a collaboration ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,359.00.